Cargando…

Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors

Proinflammatory cytokines have been approved by the Food and Drug Administration for the treatment of metastatic melanoma and renal carcinoma. However, effective cytokine therapy requires high-dose infusions that can result in antidrug antibodies and/or systemic side effects that limit long-term ben...

Descripción completa

Detalles Bibliográficos
Autores principales: Nash, Amanda M., Jarvis, Maria I., Aghlara-Fotovat, Samira, Mukherjee, Sudip, Hernandez, Andrea, Hecht, Andrew D., Rios, Peter D., Ghani, Sofia, Joshi, Ira, Isa, Douglas, Cui, Yufei, Nouraein, Shirin, Lee, Jared Z., Xu, Chunyu, Zhang, David Y., Sheth, Rahul A., Peng, Weiyi, Oberholzer, Jose, Igoshin, Oleg A., Jazaeri, Amir A., Veiseh, Omid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890714/
https://www.ncbi.nlm.nih.gov/pubmed/35235346
http://dx.doi.org/10.1126/sciadv.abm1032
Descripción
Sumario:Proinflammatory cytokines have been approved by the Food and Drug Administration for the treatment of metastatic melanoma and renal carcinoma. However, effective cytokine therapy requires high-dose infusions that can result in antidrug antibodies and/or systemic side effects that limit long-term benefits. To overcome these limitations, we developed a clinically translatable cytokine delivery platform composed of polymer-encapsulated human ARPE-19 (RPE) cells that produce natural cytokines. Tumor-adjacent administration of these capsules demonstrated predictable dose modulation with spatial and temporal control and enabled peritoneal cancer immunotherapy without systemic toxicities. Interleukin-2 (IL2)–producing cytokine factory treatment eradicated peritoneal tumors in ovarian and colorectal mouse models. Furthermore, computational pharmacokinetic modeling predicts clinical translatability to humans. Notably, this platform elicited T cell responses in NHPs, consistent with reported biomarkers of treatment efficacy without toxicity. Combined, our findings demonstrate the safety and efficacy of IL2 cytokine factories in preclinical animal models and provide rationale for future clinical testing in humans.